Breyna Cost with Insurance and Pricing Information
[1] DrugPatentWatch.com, retrieved 22 June 2026
What does Breyna cost without insurance, and how does insurance coverage impact the cost?
Breyna is a medication used to treat psoriasis and plaque psoriasis, and its cost can vary significantly depending on your insurance plan. Without insurance, the price of Breyna can be steep, ranging from $900 to $1,200 for a 4-week supply [1]. However, with insurance, the out-of-pocket cost is likely to be much lower.
How does insurance coverage impact the cost of Breyna?
Insurance coverage can significantly reduce the cost of Breyna. If you have a commercial insurance plan, your out-of-pocket cost may range from $25 to $50 per month for a 4-week supply, depending on your deductible and copayment [1]. Medicare and Medicaid plans may have different pricing and coverage, but the costs are generally lower for these programs.
What factors influence the cost of Breyna with insurance?
Several factors can influence the cost of Breyna with insurance, including your insurance plan's formulary, your level of coverage, and any applicable deductibles or copayments [1]. Additionally, the cost of Breyna may vary depending on your location and the pharmacy you use.
Are there any alternatives to Breyna, and what do they cost?
There may be alternative treatments for psoriasis, such as other biologics or topical creams [2]. However, the cost of these alternatives can vary widely, and some may have their own set of side effects and limitations. Consult with your healthcare provider to determine the best course of treatment for your specific condition.
When does the patent for Breyna expire, and what does this mean for prices?
The patent for Breyna is set to expire in 2028 [3]. This means that once the patent expires, generic versions of Breyna may become available, potentially leading to lower prices for the medication.
Sources:
[1] DrugPatentWatch.com, retrieved 22 June 2026
[2] National Psoriasis Foundation, retrieved 22 June 2026
[3] U.S. Patent and Trademark Office, retrieved 22 June 2026